biotech / news / / Devdiscourse
ICER has called for increased transparency from the U.S. Food and Drug Administration (FDA) concerning its accelerated drug approval process.
ICER is urging the FDA to provide more transparency on its accelerated drug approval process.
KEY POINTS
- FDA's use of surrogate endpoints in drug approvals is raising new reliability concerns.
- A study found tirzepatide causes more muscle loss than semaglutide in weight-loss treatment.
- OpenAI's GPT-Rosalind model was launched to enhance life sciences and biotechnology research.
- FDA may broaden testosterone therapy approval to men with idiopathic hypogonadism, not just known causes.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →